Changes in Hormonal Contraceptive Dispensing Trends Among Commercially Insured Kentucky Females During the COVID‐19 Pandemic
- 16 May 2025
- journal article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 34 (5) , e70159
Abstract
Purpose: To evaluate the impact of the COVID‐19 national emergency declaration on contraceptive dispensing trends among commercially insured Kentucky females.Methods: Data ranging from 1/7/2019 through 12/27/2020 for female enrollees aged 19–44 with a primary residence in Kentucky were extracted from the Merative Marketscan Commercial Claims and Encounters Database. A segmented regression analysis was used for statistical modeling of an interrupted time series design to describe changes in weekly contraceptive (oral, transdermal, and vaginal) dispensing rates and days' supply following the COVID‐19 national emergency.Results: A total of 90 541 enrollees met study inclusion criteria. The estimated weekly contraceptive dispensing rate per 100 reproductive‐aged female enrollees was 3.22 (95% confidence interval [CI] 3.16–3.28) at the beginning of the pre‐pandemic period. Following the national emergency, an immediate estimated rate increase of 0.11 (95% CI 0.01–0.21; p = 0.030) was seen with no change in trend. At the beginning of the pre‐pandemic period, the estimated weekly percentage of days' supply > 28 days was 29.2% (95% CI 28.8–29.6) with an increasing trend of 1.1% every 10 weeks (slope 0.11 [95% CI 0.09–0.12; p < 0.001]). Following the national emergency, an immediate decrease of 1.5% (95% CI −2.2 to −0.8; p < 0.001) was observed, followed by sustainment of the pre‐pandemic trend. No differential impacts were seen with regard to age group (19–26 vs. 27–44) or rural–urban classification.Conclusions: Following the COVID‐19 national emergency declaration, trends in both contraceptive dispensing and days' supply among commercially insured Kentucky females were relatively stable, suggesting multiple behavioral and policy‐related factors potentially overshadowing changes in access.Keywords
Funding Information
- National Institutes of Health (UL1TR001998)
This publication has 32 references indexed in Scilit:
- Contraception claims by medication for opioid use disorder prescription status among insured women with opioid use disorder, United States, 2018Contraception, 2022
- Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in FranceContraception, 2021
- Pharmacists' experiences of consumer stockpiling: insights from COVID‐19Journal of Pharmacy Practice and Research, 2021
- Declines in contraceptive visits in the United States during the COVID-19 pandemicContraception, 2021
- Factors Associated With Changes in Pregnancy Intention Among Women Who Were Mothers of Young Children in New York City Following the COVID-19 OutbreakJAMA Network Open, 2021
- Analysis of drug shortages across two countries during pre-pandemic and pandemic timesResearch in Social and Administrative Pharmacy, 2021
- The impact of the COVID-19 pandemic on economic security and pregnancy intentions among people at risk of pregnancyContraception, 2021
- Contraceptive use by disability status: new national estimates from the National Survey of Family GrowthContraception, 2018
- Racial/ethnic disparities in contraceptive use: variation by age and women's reproductive experiencesAmerican Journal of Obstetrics and Gynecology, 2014
- Medical Barriers to Effective ContraceptionObstetrics and Gynecology Clinics of North America, 2007